Assignee
DANA FARBER CANCER INST INC
US·834 granted patents·463 pending applications·12,464 citations·filing 1982–2025
Top patents by PatentIndex Score
1,297 records- 0199US4569789AAcid-cleavable compound, use in protein conjugates and drug delivery systemsDANA FARBER CANCER INST INC·Filed 1985·Granted Feb 11, 1986·458 cites·17 claims
- 0299US4542225AAcid-cleavable compoundDANA FARBER CANCER INST INC·Filed 1984·Granted Sep 17, 1985·107 cites·20 claims
- 0398US10464925B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2018·Granted Nov 5, 2019·36 cites·16 claims
- 0498US10125114B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2017·Granted Nov 13, 2018·57 cites·20 claims
- 0598US9902759B2BH3 peptides and methods of use thereofDANA FARBER CANCER INST INC·Filed 2016·Granted Feb 27, 2018·25 cites·8 claims
- 0698US9821068B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2016·Granted Nov 21, 2017·71 cites·117 claims
- 0798US9770512B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2016·Granted Sep 26, 2017·63 cites·42 claims
- 0898US9750816B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2016·Granted Sep 5, 2017·62 cites·56 claims
- 0998US9714946B2Bromodomain binding reagents and uses thereofDANA FARBER CANCER INST INC·Filed 2014·Granted Jul 25, 2017·41 cites·13 claims
- 1098US9694084B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2015·Granted Jul 4, 2017·76 cites·84 claims
- 1198US9320741B2Compositions and methods for treating neoplasia, inflammatory disease and other disordersDANA FARBER CANCER INST INC·Filed 2014·Granted Apr 26, 2016·23 cites·10 claims
- 1298US9102727B2Human anti-PD-1 antibodies and uses thereforDANA FARBER CANCER INST INC·Filed 2013·Granted Aug 11, 2015·181 cites·21 claims
- 1398US7638492B2Methods of upmodulating an immune response with non-activating forms of B7-4DANA FARBER CANCER INST INC·Filed 2006·Granted Dec 29, 2009·64 cites·7 claims
- 1498US5942607AB7-2: a CTLA4/CD28 ligandDANA FARBER CANCER INST INC·Filed 1993·Granted Aug 24, 1999·106 cites·9 claims
- 1598US4625014ACell-delivery agentDANA FARBER CANCER INST INC·Filed 1984·Granted Nov 25, 1986·255 cites·28 claims
- 1698US4618492AAcid-cleavable compoundDANA FARBER CANCER INST INC·Filed 1985·Granted Oct 21, 1986·98 cites·6 claims
- 1797US11325910B2Inhibitors of cyclin-dependent kinasesDANA FARBER CANCER INST INC·Filed 2020·Granted May 10, 2022·8 cites·24 claims
- 1897US10849980B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2019·Granted Dec 1, 2020·16 cites·45 claims
- 1997US10669253B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2018·Granted Jun 2, 2020·17 cites·19 claims
- 2097US10550121B2Inhibitors of cyclin-dependent kinasesDANA FARBER CANCER INST INC·Filed 2016·Granted Feb 4, 2020·15 cites·10 claims
- 2197US10407441B2Compositions and methods for treating neoplasia, inflammatory disease and other disordersDANA FARBER CANCER INST INC·Filed 2018·Granted Sep 10, 2019·10 cites·18 claims
- 2297US9758522B2Hydrophobically tagged small molecules as inducers of protein degradationDANA FARBER CANCER INST INC·Filed 2013·Granted Sep 12, 2017·27 cites·22 claims
- 2397US9505784B2Fused 2-aminothiazole compoundsDANA FARBER CANCER INST INC·Filed 2014·Granted Nov 29, 2016·64 cites·27 claims
- 2497US7868133B2BH3 peptides and method of use thereofDANA FARBER CANCER INST INC·Filed 2007·Granted Jan 11, 2011·46 cites·6 claims
- 2597US7723469B2Stabilized alpha helical peptides and uses thereofDANA FARBER CANCER INST INC·Filed 2004·Granted May 25, 2010·151 cites·1 claims
- 2697US7709214B2Methods for upregulating an immune response with agents that inhibit the intereaction between PD-L2 and PD-1DANA FARBER CANCER INST INC·Filed 2007·Granted May 4, 2010·153 cites·8 claims
- 2797US7635757B2B7-4 Antibodies and uses thereforDANA FARBER CANCER INST INC·Filed 2006·Granted Dec 22, 2009·267 cites·13 claims
- 2897US6936704B1Nucleic acids encoding costimulatory molecule B7-4DANA FARBER CANCER INST INC·Filed 2000·Granted Aug 30, 2005·121 cites·64 claims
- 2997US6329173B1Method of intracellular binding target moleculesDANA FARBER CANCER INST INC·Filed 2000·Granted Dec 11, 2001·81 cites·22 claims
- 3096US11583586B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2020·Granted Feb 21, 2023·3 cites·21 claims
- 3196US10011656B2Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses thereforDANA FARBER CANCER INST INC·Filed 2015·Granted Jul 3, 2018·24 cites·11 claims
- 3296US9382239B2Inhibitors of c-Jun-N-terminal kinase (JNK)DANA FARBER CANCER INST INC·Filed 2012·Granted Jul 5, 2016·30 cites·47 claims
- 3396US5965371AMethod of intracellular binding of target moleculesDANA FARBER CANCER INST INC·Filed 1995·Granted Oct 12, 1999·117 cites·101 claims
- 3496US5861310ATumor cells modified to express B7-2 with increased immunogenicity and uses thereforDANA FARBER CANCER INST INC·Filed 1995·Granted Jan 19, 1999·97 cites·10 claims
- 3596US4764368AAcid-cleavable compoundDANA FARBER CANCER INST INC·Filed 1986·Granted Aug 16, 1988·57 cites·20 claims
- 3695US10435469B2Drug delivery compositions and uses thereofDANA FARBER CANCER INST INC·Filed 2018·Granted Oct 8, 2019·15 cites·28 claims
- 3795US10413612B2Method of treating cancer with a biomaterial and a toll-like receptor agonistDANA FARBER CANCER INST INC·Filed 2018·Granted Sep 17, 2019·13 cites·28 claims
- 3895US10287268B2Imidazolyl kinase inhibitors and uses thereofDANA FARBER CANCER INST INC·Filed 2015·Granted May 14, 2019·11 cites·23 claims
- 3995US10144730B2Inhibitors of c-Jun-N-terminal kinase (JNK)DANA FARBER CANCER INST INC·Filed 2016·Granted Dec 4, 2018·16 cites·39 claims
- 4095US9527896B2Stabilized p53 peptides and uses thereofDANA FARBER CANCER INST INC·Filed 2014·Granted Dec 27, 2016·31 cites·15 claims
- 4195US9464115B2Stabilized alpha helical peptides and uses thereofDANA FARBER CANCER INST INC·Filed 2013·Granted Oct 11, 2016·29 cites·32 claims
- 4295US7700301B2Methods for screening for compounds that modulate PD-1 signalingDANA FARBER CANCER INST INC·Filed 2006·Granted Apr 20, 2010·32 cites·3 claims
- 4395US7432059B2Methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1 mediated signalDANA FARBER CANCER INST INC·Filed 2001·Granted Oct 7, 2008·119 cites·13 claims
- 4495US6015558ATreatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-α functionDANA FARBER CANCER INST INC·Filed 1998·Granted Jan 18, 2000·134 cites·5 claims
- 4595US5928647AInducing cytotoxic T lymphocyte responsesDANA FARBER CANCER INST INC·Filed 1994·Granted Jul 27, 1999·277 cites·20 claims
- 4695US5851829AMethod of intracellular binding of target moleculesDANA FARBER CANCER INST INC·Filed 1993·Granted Dec 22, 1998·152 cites·62 claims
- 4795US5730975ATreatment of insulin resistance in obesity linked type II diabetes using antagonist to TNF-alpha functionDANA FARBER CANCER INST INC·Filed 1994·Granted Mar 24, 1998·148 cites·13 claims
- 4894US11932625B2Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereofDANA FARBER CANCER INST INC·Filed 2022·Granted Mar 19, 2024·3 cites·30 claims
- 4994US11597934B2Methods and compositions for reducing immunosuppression by tumor cellsDANA FARBER CANCER INST INC·Filed 2020·Granted Mar 7, 2023·3 cites·20 claims
- 5094US10870651B2Inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2015·Granted Dec 22, 2020·9 cites·36 claims
Showing the top 50 of 1,297 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when DANA FARBER CANCER INST INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →